What is the market's earnings forecast for Moderna next quarter?

Did Moderna beat or miss consensus estimates last quarter?

What does Moderna do and what are its main business segments?

What factors drove the changes in Moderna's revenue and profit?

What were the key takeaways from Moderna’s earnings call?

What is Moderna's gross profit margin?

What guidance did Moderna's management provide for the next earnings period?

What were the key takeaways from Moderna's earnings call?

- **Revenue resilience**: 2025 revenue $1.9B, down 30% in operating expenses, with $8.1B cash despite FDA flu setback.
- **Pipeline progress**: Intismeran Phase II melanoma shows 50% relapse reduction; norovirus Phase III enrolling; PA program nearing data.
- **2026 growth**: Up to 10% revenue growth driven by international partnerships, mNEXSPIKE expansion, and flu/COVID combo vaccine filings.
- **Regulatory challenges**: FDA flu vaccine refusal delays U.S. launch, but international filings advancing.

**【CEO Summary Section】**
- 2025 revenue reached $1.9 billion, driven by COVID vaccine sales (Spikevax, mNEXSPIKE). Operating expenses decreased 30% to $2.2 billion, with a net loss of $2.8 billion.
- Disappointed by FDA's refusal-to-file for mRNA-1010 flu vaccine, highlighting regulatory uncertainty's impact on innovation.
- Commercial successes include mNEXSPIKE's U.S. launch (24% retail market share) and partnerships with Recordati (rare disease) and Mexico (respiratory vaccines).
- Pipeline progress: Intismeran Phase II melanoma data shows 50% relapse reduction; Phase II bladder cancer enrollment complete; norovirus and PA programs nearing data readouts.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $700 million (U.S. $300M, international $400M). Full-year revenue: $1.9 billion, with $100M from non-COVID products.
- Cost of sales down 41% to $868M; R&D expenses down 31% to $3.1B; SG&A down 13% to $1B.
- 2026 outlook: Revenue growth up to 10%, driven by international markets (UK, Canada, Australia). Gross margin improvement expected from manufacturing efficiencies.
- Cash costs to $4.2 billion; ending 2026 with $5.5-6.0 billion in cash, excluding credit facility draws.

**【President's Commercial Update】**
- 2026 growth drivers: Strategic partnerships (Mexico, Taiwan), mNEXSPIKE expansion, flu/COVID combo vaccine filings in Europe/Canada.
- Regulatory progress: mRNA-1010 under review in Europe, Canada, Australia; mRNA-1083 combo vaccine filings in Europe/Canada.
- Pipeline momentum: Intismeran Phase III melanoma data expected; Phase II bladder cancer fully enrolled; norovirus Phase III nearing interim analysis.
- New Chief Development Officer, Dr. David Berman, to strengthen oncology pipeline.

**【Q&A Highlights】**
- Flu vaccine regulatory challenges: FDA Type A meeting requested to understand path forward; international filings progressing.
- Intismeran Phase III melanoma data expected this year; Phase II RCC and bladder cancer readouts anticipated.
- Norovirus Phase III interim analysis possible in 2026; trivalent design targets 70% circulating strains.
- Strategic partnerships (UK, Canada, Australia) to drive 2026 revenue growth; local manufacturing to support international expansion.

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

- **Revenue Resilience**: U.S. COVID vaccine sales down 20%-40% YoY, but mNEXSPIKE captures 55% of volume. International partnerships (Canada, U.K., Australia) to drive future growth.
- **Cost Efficiency**: $900 million in 2025 cash savings, targeting $4.6 billion in cash costs. Year-end cash projected at $6.5 billion-$7 billion.
- **Pipeline Momentum**: mRNA 1010 flu vaccine and mRNA 1083 combo filings expected by Jan 2026. IntiSPOTRAN oncology program advancing with Merck. Rare disease programs (PA, MMA) nearing registration.
- **Strategic Focus**: Postponing large phase 3 trials until 2028 cash break-even. Focusing on high ROI oncology and rare disease investments.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $1 billion, driven by mNEXSPIKE (55% of COVID vaccine volume) and Spikevax. U.S. revenue guidance narrowed to $1 billion-$1.3 billion (down 20%-40% YoY). International revenue expected at $600 million-$700 million for the year.
- **Strategic Partnerships**: Canada, U.K., and Australia manufacturing facilities to begin shipments in Q4 2025 and Q1 2026. Cost reductions of $900 million in 2025 vs. prior guidance, targeting $5.3 billion in GAAP operating expenses.
- **Pipeline Progress**: mRNA 1010 (flu vaccine) and mRNA 1083 (flu + COVID combo) regulatory submissions expected by Jan 2026. CMV program discontinued due to missed efficacy endpoint.

**【CFO Financial Commentary】**
- **Financial Results**: Q3 net loss of $200 million ($0.51 EPS). Cash and investments of $6.6 billion. 2025 revenue narrowed to $1.6 billion-$2 billion (prev $1.5 billion-$2.2 billion). Cost of sales reduced 60% YoY to $207 million. R&D expenses down 30% YoY to $801 million. SG&A down 5% YoY to $268 million.
- **Cost Efficiency**: $900 million in cash cost savings vs. 2024. Targeting $4.6 billion in 2025 cash costs (down from $5.5 billion). Year-end cash projected at $6.5 billion-$7 billion.

**【President’s Pipeline Update】**
- **COVID Vaccines**: mNEXSPIKE approved in 40 countries; Spikevax updated for 2025-26 strain. Arazvia (RSV) approved in 40 countries. U.S. flu vaccine (mRNA 1010) expected to file by Jan 2026.
- **Oncology**: IntiSPOTRAN (partnered with Merck) phase 3 adjuvant melanoma trial enrolling. mRNA 4359 (cancer antigen therapy) phase 1b data positive; phase 2 trials underway.
- **Rare Diseases**: Propionic acidemia (PA) program fully enrolled; methylmalonic acidemia (MMA) trial expected to start in 2026.

**【Q&A Highlights】**
- **Expense Management**: R&D and cost of sales reductions driven by trial efficiency, manufacturing optimization, and supplier pricing. 2028 cash break-even target remains, with focus on high ROI oncology and rare disease programs.
- **CMV Program**: Discontinued due to lack of efficacy in preventing congenital CMV. Ongoing phase 2 trial in bone marrow transplant patients continues.
- **Norovirus Vaccine**: Phase 3 trial delayed due to slow case accrual; may require second season for interim analysis.
- **Strategic Deals**: Exploring partnerships for latent virus vaccines (e.g., EBV) and oncology programs post-2028 break-even.

Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript

- **Cost reduction success**: 40% YoY operating expense reduction, $400M 2025 cost savings target, 10% workforce reduction.
- **Pipeline momentum**: Phase III flu vaccine 27.4% relative efficacy in 65+; CMV trial final analysis Q4 2025 with expanded secondary endpoints.
- **Financial discipline**: 2027 cash cost target of $4.2 billion; 2025 U.S. COVID sales guidance $1.0-1.5 billion.
- **AI transformation**: 100% employee GPT adoption; AI tools enable 50% faster product planning.
- **Strategic focus**: Shift to non-seasonal products (CMV, oncology) while maintaining respiratory vaccine leadership.

**【CEO Summary Section】**
- Q2 2025 revenue of $2.1 billion and a loss of $0.8 billion were in line with expectations, reflecting seasonal respiratory vaccine demand.
- Cost reductions: 35% YoY decline in cost of sales and SG&A, $581 million reduction in operating expenses on a cash cost basis.
- Strategic priorities: 
  1. Driving use of approved products (mNEXSPIKE, mRESVIA, Spikevax COVID vaccine)
  2. Advancing pipeline (Phase III flu efficacy data, flu+COVID combo program)
  3. Financial discipline (4th consecutive quarter of double-digit R&D/SG&A reductions)
- Expanded cost reduction plan to remove $400 million from 2025 cost structure, including 10% workforce reduction.
- AI adoption: 100% of knowledge workers use ChatGPT daily; AI tools now enable deep research capabilities.

**【CFO Financial Commentary】**
- Q2 2025 financial results:
  - Net product sales: $114 million (80% U.S.-based, driven by COVID boosters)
  - Cost of sales: $119 million (105% of net product sales, up from 62% YoY)
  - R&D expenses: $700 million (-43% YoY)
  - SG&A expenses: $230 million (-14% YoY)
- Updated 2025 outlook:
  - Total revenue: $1.5-2.2 billion (down $300M high end due to U.K. shipment timing)
  - U.S. product sales: $1.0-1.5 billion
  - International product sales: $0.4-0.6 billion
  - R&D expenses: $3.6-3.8 billion
  - Cash cost target: $5.1 billion (vs. $5.5 billion prior estimate)
- 2027 operating cost targets: 
  - GAAP operating expenses: $4.9 billion (vs. $6.1 billion 2025 midpoint)
  - Cash cost: $4.2 billion (vs. $5.1 billion 2025 midpoint)
- Key cost reduction drivers: R&D wind-downs, manufacturing efficiencies, procurement savings, workforce restructuring.

**【Q&A Highlights】**
- **CMV Phase III trial**: Secondary endpoints added to assess virus shedding and chronic disease impact; final analysis expected Q4 2025.
- **Flu+COVID combo vaccine**: Concurrent FDA submission possible, but flu monotherapy approval likely precedes combo filing.
- **COVID vaccine demand**: U.S. spring booster season down 10-11% YoY, but 65+ population vaccination rates stable; cautious optimism for fall season.
- **Oncology pipeline**: Intismeran Phase II first-line melanoma trial underway; Merck co-funding 50% of intismeran costs.
- **AI adoption**: GPT tools used for target product profile creation, reducing planning time by 50%.
- **CMV commercial strategy**: Real-world evidence generation planned post-approval to demonstrate long-term benefits.


Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript

- **Cost Efficiency Success**: 19% YoY reduction in R&D, SG&A, and cost of sales; 2026-2027 cost-cutting plan targets $4.2 billion 2027 cash cost.
- **Pipeline Momentum**: CMV Phase 3 durability data shows 3-year neutralizing antibody stability; INT Phase 3 melanoma trial fully enrolled.
- **Flu+COVID Combo Delay**: FDA requires flu efficacy data submission, pushing approval to 2026.
- **Oncology Focus**: Checkpoint program (mRNA-4359) prioritized over younger adult flu+COVID combo vaccine.
- **FDA Confidence**: No political interference signals; constructive interactions across all programs.


**【CEO Opening Remarks】**
- Q1 2025 revenue was $0.1 billion, in line with expectations due to seasonal respiratory vaccine demand. Net loss was $1 billion, reflecting lower sales volume and cost of sales efficiency improvements.
- 19% year-over-year reduction in combined R&D, SG&A, and cost of sales, driven by operational efficiency and cost-cutting initiatives.
- Expanded market access for mRESVIA in Australia, Taiwan, UK, and Switzerland, with US, EU, and Canada approvals in 2024.
- Phase 3 flu program exceeded case accrual targets for interim efficacy analysis, with RSV, CMV, and INT programs showing encouraging data.

**【CFO Financial Review】**
- Q1 2025 net product sales: $86 million (US 33%, international 67%), down 35% YoY due to lower vaccination rates.
- R&D expenses: $856 million (-19% YoY), driven by reduced respiratory program spend and investments in norovirus and oncology.
- SG&A: $212 million (-23% YoY), reflecting broad-based cost reductions.
- Full-year 2025 revenue guidance: $1.5-2.5 billion, with H1 sales ~$0.2 billion (seasonal).
- 2026-2027 cost reduction plan: $1.4-1.7 billion, targeting $4.2 billion 2027 cash cost and 2028 breakeven.

**【President Stephen Hoge Pipeline Update】**
- Respiratory portfolio: Next-gen COVID (PDUFA May 31), RSV (PDUFA June 12), flu+COVID combo (PDUFA Nov 2025, delayed due to flu efficacy data requirement).
- CMV: Phase 3 durability data shows 3-year neutralizing antibody stability; interim efficacy analysis expected Q3 2025.
- Norovirus: Phase 3 trial lifted from clinical hold, fully enrolled in Northern Hemisphere, Southern Hemisphere enrollment ongoing.
- Oncology: INT Phase 3 melanoma trial fully enrolled; Checkpoint program (mRNA-4359) Phase 2 expansion in melanoma and NSCLC.

**【Q&A Highlights】**
- **Flu+COVID Combo Vaccine**: FDA requires standalone flu efficacy data submission, delaying approval to 2026. Phase 3 flu efficacy study exceeded case accrual targets, interim analysis expected summer 2025.
- **FDA Interactions**: Constructive engagement across all programs; no indication of political interference in review timelines.
- **Cost Reduction Drivers**: R&D (66% of expense base) through trial wind-downs, procurement savings, and process efficiencies.
- **Oncology Prioritization**: Reprioritized Checkpoint program (mRNA-4359) over younger adult flu+COVID combo vaccine, reflecting clinical data confidence.
- **Political Environment**: Secretary RFK's comments on multi-antigen vaccines not impacting Moderna's single-antigen strategy; focus on data-driven decision-making.


Moderna (MRNA)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue decline**: 2024 revenue ($3.2B) down 53% YoY due to COVID vaccine market contraction. 
- **Cost efficiency**: $2.6B OpEx savings (27% YoY reduction) and $5.5B 2025 cash cost target. 
- **Pipeline momentum**: 10 high-value assets targeting $30B+ TAM, with 3 filed for approval in 2024. 
- **Key 2025 focus**: Breakeven by 2028, $1.5-2.5B revenue guidance, and INT melanoma Phase 3 readout potential in 2026.

**【CEO 2024 Year Review】**
- Total revenue: $3.2 billion (down 53% YoY due to lower COVID vaccine sales). 
- Cost savings: $2.6 billion (27% YoY reduction in OpEx, CapEx, and working capital). 
- Cash balance: $9.5 billion at year-end (up from $9.2 billion Q3). 
- Key programs: 10 high-value pipeline assets targeting $30+ billion TAM, including next-gen COVID, RSV, flu, CMV, and oncology vaccines.

**【CFO 2024 Financial Results】**
- Q4 net product sales: $966 million (down 66% YoY). 
- Full year R&D expenses: $4.5 billion (6% YoY decline). 
- 2025 financial outlook: 
  - Revenue: $1.5-2.5 billion (includes $0.2 billion H1 sales). 
  - Cash costs: $5.5 billion (down $1 billion YoY). 
  - End 2025 cash: ~$6 billion.

**【Clinical Program Updates】**
- Respiratory vaccines: 
  - Next-gen COVID (mRNA-1283) filed in multiple markets (US PDUFA: May 31). 
  - RSV (mRESVIA) for high-risk adults (18-59) filed globally (US PDUFA: June 12). 
  - Flu-COVID combo vaccine awaiting flu efficacy data from standalone mRNA-1010 trial. 
- Oncology: INT (mRNA-4157) Phase 3 adjuvant melanoma trial fully enrolled. 
- Rare diseases: 
  - PA (Propionic acidemia) registrational study ongoing. 
  - MMA (Methylmalonic acidemia) pivotal study design agreed with FDA.

**【2025 Priorities】**
1. Drive sales of approved products (Spikevax, mRESVIA). 
2. Deliver 10 product approvals over next 3 years. 
3. Achieve cash breakeven by 2028 through $1+ billion annual cost savings. 
4. Reduce R&D expenses to $3.6-3.7 billion by 2027 (from $4.8 billion 2024 level).

Actual						-0.35	-0.31	-0.59	-0.69	2.84	6.46	7.7	11.29	8.58	5.24	2.53	3.61	0.19	-3.62	-9.53	0.55	-3.07	-3.33	0.03	-2.91	-2.52	-2.13	-0.51	-2.11
Forecast						-0.3544	-0.3527	-0.3782	-0.3425	2.4317	5.9551	8.9728	9.9618	5.3729	4.5834	3.2981	4.6008	-1.7474	-3.9347	-1.9323	-0.9868	-3.5567	-3.3482	-1.8045	-2.6804	-3.116	-2.9893	-1.8746	-2.5442
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	+1.24%	+12.11%	-56.00%	-101.46%	+16.79%	+8.48%	-14.19%	+13.33%	+59.69%	+14.33%	-23.29%	-21.54%	+110.87%	+8.00%	-393.19%	+155.74%	+13.68%	+0.54%	+101.66%	-8.57%	+19.13%	+28.75%	+72.79%	+17.07%

MRNA

MRNA fundamentals

MRNA Q4 2025 Earnings

Earnings Call

You can ask Aime

MRNA

MRNA fundamentals

MRNA Q4 2025 Earnings

Earnings Call

MRNA Earnings Call Summary for Q4/20258:00 AM on Feb 13, 2026

MRNA Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

MRNA Earnings Call Summary for Q2/20258:00 AM on Aug 1, 2025

MRNA Earnings Call Summary for Q1/20258:00 AM on May 1, 2025

MRNA Earnings Call Summary for Q4/20248:00 AM on Feb 14, 2025

You can ask Aime